Merck is reporting a 12% jump in global sales, pushing it past profit expectations for the second quarter.
The pharmaceutical company reported a profit of $2.67 billion, or $1.03 per share. Earnings, adjusted for costs related to mergers and acquisitions and restructuring costs, were $1.30 per share, which is 14 cents better than Wall Street had anticipated, according to a survey by Zacks Investment Research.
The Kenilworth, New Jersey-based had revenue of $11.76 billion in the period.
Merck expects full-year earnings in the range of $4.84 to $4.94 per share, with revenue in the range of $45.2 billion to $46.2 billion.
Shares of Merck & Co. rose 5% before the opening bell Tuesday.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRK at https://www.zacks.com/ap/MRK